We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+44.59%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$740M
AUM Growth
+$197M
Cap. Flow
+$29.1M
Cap. Flow %
3.93%
Top 10 Hldgs %
100%
Holding
11
New
2
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$23.7M
2
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$4.21M
3
CLRB icon
Cellectar Biosciences
CLRB
+$1.55M

Top Sells

Rank Stock Value
1
EQ icon
Equillium
EQ
+$379K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
1
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$516M 69.79%
14,075,269
+989,231
+8% +$23.7M
HRTX icon
2
Heron Therapeutics
HRTX
$86.3M
$107M 14.43%
5,744,096
– –
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
$45.7M 6.17%
4,938,893
– –
RCKT icon
4
Rocket Pharmaceuticals
RCKT
$348M
$44.5M 6.01%
2,965,485
– –
CELG
5
DELISTED
Celgene Corp
CELG
$10.3M 1.4%
111,844
– –
GTHX
6
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.13M 0.83%
+200,000
New +$4.21M
PBYI icon
7
Puma Biotechnology
PBYI
$406M
$4.44M 0.6%
349,400
– –
PRTA icon
8
Prothena Corp
PRTA
$458M
$3.42M 0.46%
323,823
– –
CLRB icon
9
Cellectar Biosciences
CLRB
$19.3M
$1.48M 0.2%
+2,267
New +$1.55M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$780K 0.11%
600,000
– –
EQ icon
11
Equillium
EQ
$157M
– –
-47,343
Closed -$379K

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $1.98B AUM 1.62% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return

Tang Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tang Capital Management held 11 positions worth $740M, up 36% from $543M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Tang Capital Management deployed $29.1M of net new capital in Q2 2019, opening 2 new positions and adding to 1 existing holding. Its largest new stake was G1 Therapeutics, Inc. Common Stock: 200,000 shares worth $6.13M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Equillium, an estimated $379K sold.

  • Tang Capital Management's largest Q2 2019 buy was G1 Therapeutics, Inc. Common Stock: 200,000 shares worth $6.13M.
  • Tang Capital Management added most to Odonate Therapeutics, Inc. Common Stock in Q2 2019, an estimated $23.7M increase.
  • Tang Capital Management fully exited Equillium in Q2 2019, selling an estimated $379K.
  • Tang Capital Management's ten largest holdings make up 100% of its $740M portfolio in Q2 2019.
  • Tang Capital Management opened 2 new positions and closed 1 in Q2 2019.
  • Tang Capital Management's portfolio value rose 36% quarter-over-quarter to $740M.

Based on Tang Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.